肠道菌群影响慢性乙型肝炎、慢性丙型肝炎及相关肝病的研究进展  

Research advances in the role of gut microbiota in chronic hepatitis B,chronic hepatitis C,and related liver diseases

作　　者：邓辉[1] 张斌[1] 朱彬 迪丽胡玛尔·扎依尔 王伟仙 郭春霞 杨东亮[1] 郑昕[1] 王俊忠 王宝菊[1] DENG Hui;ZHANG Bin;ZHU Bin;DILIHUMAER Zhayier;WANG Weixian;GUO Chunxia;YANG Dongliang;ZHENG Xin;WANG Junzhong;WANG Baoju(Department of Infectious Diseases,Union Hospital,Tongji Medical College,Huazhong University of Science and Technology,Wuhan 430022,China)

机构地区：[1]华中科技大学同济医学院附属协和医院感染性疾病科,武汉430022

出　　处：《临床肝胆病杂志》2022年第5期1143-1147,共5页Journal of Clinical Hepatology

基　　金：国家传染病科技重大专项课题(2017ZX10304402-002-005)。

摘　　要：HBV、HCV感染常可进展为肝硬化、肝衰竭和肝细胞癌等终末期肝病,危及患者生命。近年来研究发现肠道菌群与慢性病毒性肝病关系密切。本文就肠道菌群与慢性乙型肝炎、慢性丙型肝炎及其相关肝病之间的相关性,以及靶向肠道菌群治疗慢性乙型肝炎及其相关肝病的研究进展进行了综述,以期为临床治疗慢性乙型肝炎、慢性丙型肝炎及其相关肝病提供更多思考。Hepatitis B virus infection and hepatitis C virus infection often progress to end-stage liver diseases such as liver cirrhosis,liver failure,and hepatocellular carcinoma,which endanger the life of patients.Recent studies have shown that gut microbiota are closely associated with chronic viral liver diseases.This article reviews the association of gut microbiota with chronic hepatitis B(CHB),chronic hepatitis C(CHC),and their related liver diseases and the research advances in therapies targeting gut microbiota against CHB and its related liver diseases,in order to provide more ideas for the clinical treatment of CHB,CHC,and their related liver diseases.

关 键 词：肝炎病毒 胃肠道微生物组 肝硬化 肝功能衰竭 治疗学 

分 类 号：R51[医药卫生—内科学]